With in-depth research on lung cancer genotyping and the rapid development of molecular targeted therapies, targeted therapy has become the standard first-line treatment for advanced NSCLC patients with driver gene mutations (such as EGFR and ALK) [3, 4]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.